These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 15071285)
1. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Golombek SG; Berning F; Lagamma EF Pediatr Infect Dis J; 2004 Apr; 23(4):318-22. PubMed ID: 15071285 [TBL] [Abstract][Full Text] [Related]
2. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495 [TBL] [Abstract][Full Text] [Related]
3. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry. Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J; Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822 [TBL] [Abstract][Full Text] [Related]
4. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan. Diehl JL; Daw JR; Coley KC; Rayburg R J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844 [TBL] [Abstract][Full Text] [Related]
5. Home delivery of palivizumab: outcomes and compliance in regional preterm infants. Paul DA; Leef KH; Chidekel A; Tran K; Eppes S; Stefano JL Del Med J; 2002 Jan; 74(1):11-5. PubMed ID: 11838265 [TBL] [Abstract][Full Text] [Related]
7. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Romero JR Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452 [TBL] [Abstract][Full Text] [Related]
8. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P; Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374 [TBL] [Abstract][Full Text] [Related]
9. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease? Elhassan NO; Stevens TP; Sorbero ME; Dick AW; Guillet R; Hall CB Pediatr Infect Dis J; 2003 Nov; 22(11):939-43. PubMed ID: 14614363 [TBL] [Abstract][Full Text] [Related]
10. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Paes B; Steele S; Janes M; Pinelli J Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698 [TBL] [Abstract][Full Text] [Related]
11. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
12. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Law BJ; Langley JM; Allen U; Paes B; Lee DS; Mitchell I; Sampalis J; Walti H; Robinson J; O'Brien K; Majaesic C; Caouette G; Frenette L; Le Saux N; Simmons B; Moisiuk S; Sankaran K; Ojah C; Singh AJ; Lebel MH; Bacheyie GS; Onyett H; Michaliszyn A; Manzi P; Parison D Pediatr Infect Dis J; 2004 Sep; 23(9):806-14. PubMed ID: 15361717 [TBL] [Abstract][Full Text] [Related]
14. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. Fernández P; Trenholme A; Abarca K; Griffin MP; Hultquist M; Harris B; Losonsky GA; BMC Pediatr; 2010 Jun; 10():38. PubMed ID: 20525274 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus. Ohler KH; Pham JT Am J Health Syst Pharm; 2013 Aug; 70(15):1342-6. PubMed ID: 23867491 [TBL] [Abstract][Full Text] [Related]
16. Factors predicting compliance with palivizumab in high-risk infants. Langkamp DL; Hlavin SM Am J Perinatol; 2001 Sep; 18(6):345-52. PubMed ID: 11607852 [TBL] [Abstract][Full Text] [Related]
17. A 4-year survey on palivizumab respiratory syncytial virus (RSV)-prophylaxis: how can compliance be improved? Pignotti MS; Catarzi S; Donzelli G J Matern Fetal Neonatal Med; 2006 Apr; 19(4):221-4. PubMed ID: 16854695 [TBL] [Abstract][Full Text] [Related]
18. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. Fenton C; Scott LJ; Plosker GL Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364 [TBL] [Abstract][Full Text] [Related]
19. Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland. Borecka R; Lauterbach R; Helwich E Dev Period Med; 2016; 20(3):181-190. PubMed ID: 27941187 [TBL] [Abstract][Full Text] [Related]